Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus adalimumab biosimilar for radiographic progression in active ankylosing spondylitis
MOH_2018-05-31_002265Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of secukinumab and adalimumab in ankylosing spondylitis (AS) (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started May 2018; status: completed.
02
Drugs
secukinumabadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on MOH_2018-05-31_002265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-31_002265.